Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial.

[1]  G. Fonarow,et al.  Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. , 2007, European heart journal.

[2]  Ho-Shik Kim,et al.  Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys , 2019, Front. Physiol..

[3]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[4]  C. Lang,et al.  Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure , 2020, Circulation.

[5]  J. McMurray,et al.  Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis , 2018, Diabetes, obesity & metabolism.

[6]  E. Herzog,et al.  Hyponatremia in Heart Failure: Pathogenesis and Management , 2019, Current cardiology reviews.

[7]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[8]  C. O'connor,et al.  Hyponatremia and long-term outcomes in chronic heart failure--an observational study from the Duke Databank for Cardiovascular Diseases. , 2012, Journal of cardiac failure.

[9]  J. Dasta,et al.  Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial , 2012, Journal of medical economics.

[10]  D. Sica.  Hyponatremia and heart failure--pathophysiology and implications. , 2005, Congestive heart failure.

[11]  Kamlesh Khunti,et al.  Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. , 2020, The lancet. Diabetes & endocrinology.

[12]  G. Laverman,et al.  Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors , 2019, Journal of clinical medicine.

[13]  J. Atherton,et al.  Hyponatraemia in heart failure , 2020, Internal medicine journal.

[14]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[15]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[16]  A. Amin,et al.  Current Management of Hyponatremia in Acute Heart Failure: A Report From the Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia (HN Registry) , 2017, Journal of the American Heart Association.

[17]  N. Madias,et al.  Diagnosis and treatment of hyponatremia. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  H. Jneid,et al.  Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions. , 2014, The American journal of cardiology.

[19]  Jeffrey M. Turner,et al.  Empagliflozin in Heart Failure , 2020, Circulation.

[20]  H. Koepsell,et al.  Osmotic diuresis by SGLT2 inhibition stimulates vasopressin‐induced water reabsorption to maintain body fluid volume , 2020, Physiological reports.

[21]  P. Hildebrandt,et al.  Prevalence and prognostic significance of hyponatraemia in outpatients with chronic heart failure , 2011, European journal of heart failure.

[22]  Jiannan Li.  ASSOCIATION OF PLASMA TRIMETHYLAMINE N-OXIDE LEVEL WITH HEALED CULPRIT PLAQUES EXAMINED BY OPTICAL COHERENCE TOMOGRAPHY IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION , 2020 .

[23]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[24]  D. J. Veldhuisen,et al.  Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure , 2020, European journal of heart failure.

[25]  B. Perkins,et al.  Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function. , 2020, Kidney international.

[26]  H. Heerspink,et al.  A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. , 2021, Cell metabolism.

[27]  M. Gheorghiade,et al.  Hyponatremia and in-hospital mortality in patients admitted for heart failure (from the ATTEND registry). , 2013, The American journal of cardiology.

[28]  Mark Woodward,et al.  Risk prediction in patients with heart failure: a systematic review and analysis. , 2014, JACC. Heart failure.